# HotSpot Therapeutics

Source: https://onco.cc/companies/hotspot-therapeutics/  
OnCo record `hotspot-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HotSpot Therapeutics is a Boston biotech that drugs the regulatory pockets of proteins rather than their active sites; its oral CBL-B inhibitor HST-1011 releases a brake on T cells.

## Summary

HotSpot Therapeutics targets natural regulatory hotspots, allosteric sites that control protein function, using its Smart Allostery platform. Its first clinical candidate HST-1011 is an oral allosteric inhibitor of the E3 ubiquitin ligase CBL-B, an intracellular checkpoint that limits T-cell and natural killer cell activation. HST-1011 is in a phase 1/2 trial alone and with cemiplimab in advanced solid tumours; the company also develops an IRF5 inhibitor for autoimmune disease.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: HotSpot Therapeutics, Inc.
- Tags: drug-maker
- HQ: Boston, Massachusetts
- Type: biotech
- Website: https://www.hotspotthera.com/

## Sources

- Official website: https://www.hotspotthera.com/

## Connected records

- drugs: [HST-1011](https://onco.cc/drugs/hst-1011/)

---
JSON: https://onco.cc/api/v1/entities/hotspot-therapeutics.json